Poseida Therapeutics, Inc.
PSTXDelisted Jan 8, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001661460
Poseida Therapeutics, Inc. was delisted on Jan 8, 2025; its insiders filed their last Form 4 on Jan 10, 2025; 116 institutions reported holding it in 13F filings for Q4 2024, worth $519.2M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Poseida Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Poseida Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Malin Life Sciences Holdings Ltd | 10% Owner | 0 | Jan 10, 2025 | 0 |
| Leonhardt Harry J | GC & Chief Compliance Officer | 0 | Jan 8, 2025 | 0 |
| Gergen Mark J | President and CEO | 0 | Jan 8, 2025 | 0 |
| Lloyd Marcea Bland | Director | 0 | Jan 8, 2025 | 0 |
| Collins Cynthia | Director | 0 | Jan 8, 2025 | 0 |
| Schmid John P. | Director | 0 | Jan 8, 2025 | 0 |
| Baum Charles M | Director | 0 | Jan 8, 2025 | 0 |
| Amado Rafael | Director | 0 | Jan 8, 2025 | 0 |
| Mylet Johanna | Chief Financial Officer | 0 | Jan 8, 2025 | 0 |
| Yarema Kristin | President and CEO | 0 | Jan 8, 2025 | 0 |
| Corning Luke | Director | 0 | Jan 8, 2025 | 0 |
| Rizvi Syed Ali-aamir | Chief Medical Officer | 0 | Jan 8, 2025 | 0 |
| Warner Brent | President, Gene Therapy | 419,040 | Mar 4, 2024 | 0 |
| Ostertag Eric | Director | 827,320 | Feb 3, 2023 | 0 |
| Ingalls Kerry D. | Chief Operating Officer | 55,000 | Mar 18, 2022 | 0 |
| Spear Matthew A. | Chief Medical Officer | 111,485 | Mar 1, 2022 | 0 |
| Hirsch David | Director | – | Jul 26, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 11, 2024 (view filing) | Dec 10 | 1 day | Gergen Mark JExecutive Chairman | SSale | −30.0K | $9.46 | −$283.8K | −4.4%651.3K after | 10b5-1 |
| Nov 27, 2024 (view filing) | Nov 26 | 1 day | Gergen Mark JExecutive Chairman | SSale | −30.0K | $9.27 | −$278.1K | −4.4%651.3K after | 10b5-1 |
| Aug 10, 2022 (view filing) | Aug 8 | 2 days | Ostertag EricExecutive Chairman | PPurchase | +142.9K | $3.50 | +$500.0K | +20.5%838.8K after | |
| Aug 10, 2022 (view filing) | Aug 8 | 2 days | Malin Life Sciences Holdings Ltd10% Owner | PPurchase | +2.15M | $3.50 | +$7.53M | +22.2%11.8M after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Ostertag EricExecutive Chairman | SSale | −160.7K | $3.69 | −$593.0K | −100.0%0 after | |
| Mar 18, 2022 (view filing) | Mar 16 | 2 days | Ingalls Kerry D.Chief Operating Officer | PPurchase | +3.00K | $3.98 | +$11.9K | +5.8%55.0K after | |
| Dec 7, 2021 (view filing) | Dec 6 | 1 day | Malin Life Sciences Holdings Ltd10% Owner, Other: Common director with Issuer | PPurchase | +1.83K | $6.90 | +$12.6K | 0.0%9.69M after | |
| Dec 2, 2021 (view filing) | Nov 30-Dec 2 | 2 days | Malin Life Sciences Holdings Ltd10% Owner, Other: Common director with Issuer | PPurchase | +51.3K | $6.85 | +$351.2K | +0.5%9.68M after | 3 lots |
| Nov 29, 2021 (view filing) | Nov 24-29 | 5 days | Malin Life Sciences Holdings Ltd10% Owner, Other: Common director with Issuer | PPurchase | +39.4K | $6.83 | +$269.0K | +0.4%9.63M after | 3 lots |
| Nov 23, 2021 (view filing) | Nov 19-23 | 4 days | Malin Life Sciences Holdings Ltd10% Owner, Other: Common director with Issuer | PPurchase | +25.7K | $7.06 | +$181.6K | +0.3%9.59M after | 2 lots |
| Nov 18, 2021 (view filing) | Nov 17 | 1 day | Ingalls Kerry D.Chief Operating Officer | PPurchase | +2.00K | $7.00 | +$14.0K | New position2.00K after | |
| Nov 18, 2021 (view filing) | Nov 16-18 | 2 days | Malin Life Sciences Holdings Ltd10% Owner, Other: Common director with Issuer | PPurchase | +379.4K | $7.20 | +$2.73M | +4.1%9.57M after | 3 lots |
| Nov 10, 2021 (view filing) | Nov 8 | 2 days | Ostertag EricChief Executive Officer | SSale | −18.9K | $7.09 | −$134.2K | −0.6%3.36M after | 2 lots |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Ostertag EricChief Executive Officer | SSale | −20.0K | $7.02 | −$140.6K | −0.6%3.37M after | 2 lots |
| Sep 22, 2021 (view filing) | Sep 20 | 2 days | Ostertag EricChief Executive Officer | SSale | −20.0K | $8.00 | −$160.0K | −11.1%160.7K after | |
| Sep 15, 2021 (view filing) | Sep 14 | 1 day | Ostertag EricChief Executive Officer | SSale | −20.0K | $8.14 | −$162.8K | −10.0%180.7K after | |
| Sep 3, 2021 (view filing) | Sep 1-2 | 2 days | Ostertag EricChief Executive Officer | SSale | −112.4K | $8.39 | −$943.6K | −3.2%3.38M after | 4 lots |
| Aug 24, 2021 (view filing) | Aug 20 | 4 days | Spear Matthew A.Chief Medical Officer | SSale | −4.00K | $8.79 | −$35.2K | −8.8%41.5K after | |
| Aug 4, 2021 (view filing) | Aug 2-3 | 2 days | Ostertag EricChief Executive Officer | SSale | −33.7K | $8.05 | −$271.0K | −1.0%3.43M after | 4 lots |
| Jul 6, 2021 (view filing) | Jul 1-2 | 5 days | Ostertag EricChief Executive Officer | SSale | −48.1K | $9.28 | −$446.2K | −1.4%3.45M after | 6 lots |